31/08/2020
VBI Vaccines skyrockets to 62 percent after Raymond James analyst raises price target to $9.
VBI Vaccines ‘ stock (NASDAQ: VBIV) skyrocketed 62 percent, after Raymond James financial adviser Steven Seedhouse upgraded the stock to a strong buy and a price target of $9. VBI Vaccines also announced two COVID-19 candidates for further development. Both VBI-2901 and VBI-2902 have the potential...